Dr. Reddy's inks pact with Singapore firm to sell Trastuzumab biosimilar

 Prestige BioPharma Ltd announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Trastuzumab biosimilar

Prestige BioPharma Ltd, a Singapore-based firm, and Dr. Reddy's Laboratories Ltd., on Thursday, announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of the former's proposed Trastuzumab biosimilar in select countries in Latin America and Southeast Asia.

Prestige BioPharma's Trastuzumab (HD201) is a proposed biosimilar to Roche's Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer, a regulatory filing from the Indian drugmaker said.

Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells, it said.

Under the partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy's will be responsible for local registrations, marketing, and sales in the licensed territories.

Lisa S Park, CEO of Prestige BioPharma, commented: "We are delighted to establish a partnership with Dr. Reddy's for key Latin American and Southeast Asian markets. Dr. Reddy is the ideal partner to commercialize our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets."